Logo
x

Search category

Subscribe Now

Episodic Cluster Headache

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in P-III Study for Episodic Cluster Headache

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in P-III Study for Episodic Cluster Headache

  • July 11, 2019
Eli Lilly's Emgality (galcanezumab-gnlm) Receives FDA's Approval for Episodic Cluster Headache in Adults

Eli Lilly's Emgality (galcanezumab-gnlm) Receives FDA's Approval for Episodic Cluster Headache in Adults

  • June 5, 2019
Teva Discontinues its P-III ENFORCE Study of Fremanezumab for Episodic Cluster Headache

Teva Discontinues its P-III ENFORCE Study of Fremanezumab for Episodic Cluster Headache

  • April 24, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.